immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndromeTrials & approvals
Novartis has paused multiple studies of its CAR T candidate following three patient deaths linked to immune effector cell-associated hemophagocytic syndrome. Bristol Myers Squibb also halted some CAR T trials due to observed inflammatory events, raising safety concerns in the CAR T therapy landscape.
Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases of immune effector cell-associated hemophagocytic syndrome. BMS, meanwhile, paused some CAR T trials after separately observing “transient and reversible inflammatory events" with its therapy.
Original title: “Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events”